Your browser doesn't support javascript.
loading
Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie, Xueqing; Zhao, Yu; Tang, Hua; Zhang, Zhongrui; Liao, Junzhuo; Almodovar-Rivera, Chelsi M; Sundaresan, Ramya; Xie, Haibo; Guo, Le; Wang, Bo; Guan, Hongqing; Xing, Yongna; Tang, Weiping.
Afiliação
  • Nie X; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Zhao Y; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Tang H; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Zhang Z; Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Liao J; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Almodovar-Rivera CM; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Sundaresan R; Department of Oncology, UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Xie H; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Guo L; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Wang B; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Guan H; Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Xing Y; Department of Oncology, UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Tang W; Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Chembiochem ; 25(4): e202300685, 2024 02 16.
Article em En | MEDLINE | ID: mdl-38116854
ABSTRACT
Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4CRBN to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, which exert high selectivity over the well-known CRBN neo-substrates of IMiDs by structure-based design. They were further utilized to construct bromodomain-containing protein 4 (BRD4) degraders, which successfully depleted BRD4 in the tested cells. Overall, we reported a series of functionalized CRBN recruiters that circumvent the promiscuity from traditional IMiDs, and this study is informative to the development of selective CRBN-recruiting PROTACs for many other therapeutic targets.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeo Hidrolases / Ftalimidas / Proteínas Nucleares Idioma: En Revista: Chembiochem Assunto da revista: BIOQUIMICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeo Hidrolases / Ftalimidas / Proteínas Nucleares Idioma: En Revista: Chembiochem Assunto da revista: BIOQUIMICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos